Panagora Asset Management Inc. Grows Stock Holdings in Bristol Myers Squibb Company $BMY

Panagora Asset Management Inc. boosted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 11.7% in the 4th quarter, Holdings Channel reports. The fund owned 3,295,820 shares of the biopharmaceutical company’s stock after buying an additional 345,009 shares during the period. Bristol Myers Squibb makes up 0.6% of Panagora Asset Management Inc.’s investment portfolio, making the stock its 25th largest position. Panagora Asset Management Inc.’s holdings in Bristol Myers Squibb were worth $177,777,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in BMY. Brighton Jones LLC lifted its position in shares of Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after buying an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC boosted its position in shares of Bristol Myers Squibb by 59.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after acquiring an additional 2,786 shares during the last quarter. United Bank increased its stake in Bristol Myers Squibb by 15.0% during the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after acquiring an additional 3,277 shares during the last quarter. Marshall Wace LLP acquired a new position in Bristol Myers Squibb in the second quarter valued at about $221,000. Finally, Nebula Research & Development LLC acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $405,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst commentary highlighted that BMY’s growth portfolio now generates more than half of revenue, with Reblozyl, Breyanzi and Cobenfy delivering strong gains that help balance declines in legacy products. Article Title
• Positive Sentiment: Bristol Myers Squibb advanced its Phase 1 liver study for BMS-986435, adding another pipeline update that supports long-term growth prospects. Article Title
• Positive Sentiment: The company also reported momentum in its mavacamten heart-drug franchise, with a real-world study signaling continued traction in the cardiovascular market. Article Title
• Neutral Sentiment: Bristol Myers is rolling out an AI-driven procurement overhaul and expanding an oncology collaboration with Arcus Biosciences, which could improve efficiency and bolster its cancer pipeline over time. Article Title
• Neutral Sentiment: Erste Group made only small tweaks to earnings estimates, leaving FY2026 in line with consensus and slightly trimming FY2027, a mixed signal that does not materially change the near-term outlook. Article Title
• Negative Sentiment: Takeda said its AI-designed psoriasis pill beat Bristol Myers’ Sotyktu in a head-to-head trial, raising competitive concerns for one of BMY’s dermatology assets. Article Title

Insiders Place Their Bets

In related news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.05% of the stock is currently owned by insiders.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $57.05 on Monday. The company has a market cap of $116.49 billion, a P/E ratio of 16.02, a PEG ratio of 0.16 and a beta of 0.24. The firm has a fifty day moving average price of $57.73 and a 200 day moving average price of $56.94. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.Bristol Myers Squibb’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the firm earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts predict that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. HSBC boosted their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a report on Tuesday, March 17th. Guggenheim reaffirmed a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Wall Street Zen cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 6th. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Finally, Barclays started coverage on shares of Bristol Myers Squibb in a report on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price objective for the company. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus price target of $61.31.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.